This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by Azienda Ospedaliera Universitaria Policlinico.
Recruitment status was:  Recruiting
Università Politecnica delle Marche
Information provided by:
Azienda Ospedaliera Universitaria Policlinico Identifier:
First received: December 13, 2007
Last updated: September 2, 2009
Last verified: September 2009
The purpose of this study is to verify effect and tolerability of imatinib on pulmonary and skin fibrosis in patients affected by systemic sclerosis.

Condition Intervention Phase
Systemic Sclerosis Drug: Imatinib Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study

Resource links provided by NLM:

Further study details as provided by Azienda Ospedaliera Universitaria Policlinico:

Primary Outcome Measures:
  • Improvement of the pulmonary interstitial disease, evaluated by spirometry and DLCO, lung HRCTscan, emogasanalysis. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Cutaneous Involvement, evaluated by the modified Rodnan skin score; quality of life and patient physical and emotional well being, evaluated by SF-36 score and HAQ [ Time Frame: 1 year ]

Estimated Enrollment: 30
Study Start Date: February 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Imatinib 200 mg p.o. once a day for 6 months
Drug: Imatinib
200 mg p.o. once a day for 6 months

  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • SSc with active pulmonary involvement refractory to conventional immunosuppressive regimen
  • Presence of active interstitial alveolitis (presence of grade 2 exertional dyspnea according to Mahler Dyspnea Index AND worsening of lung function tests PLUS interstitial alveolitis assessed by HRCTscan, ground-glass pattern involving at least two lung segments OR dyspnea (as defined above)PLUS Interstitial alveolitis assessed by HRCTscan (AS DEFINED ABOVE) AND neutrophilic or eosinophilic alveolitis detected through broncoalveolar lavage
  • Resistance to conventional immunosuppressive treatment (worsening or lack of improvement of lung function tests after cyclophosphamide therapy, conducted for at least three months, with a cumulative dosage > or = 6 g
  • Age 18-80 years
  • Ability ti give an informed consent
  • Use of an acceptable method of birth control; pregnancy will be ruled out before study beginning

Exclusion Criteria:

  • Connective tissue diseases other than SSc
  • Smoking Habit
  • Pregnancy or lactation
  • HBV or HCV infection
  • Severe anaemia (Hb< or = 8g/dl)
  • Hepatic disease (ALT or ALP>1.5 fold above normal levels)
  • Moderate or severe renal failure (creatinine clearance<59ml/min)
  • Severe heart failure, with ejection fraction < or = 35% measured by echocardiography
  • thyroid disease with clinical evidence of hyperthyroidism treated with substitutive therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00573326

Contact: Paolo Fraticelli, Dr +390715964256
Contact: Armando Gabrielli, Professor +390712206104

Università Politecnica delle Marche Recruiting
Ancona, Italy, 60020
Contact: Paolo Fraticelli, Dr    +390715964256   
Sponsors and Collaborators
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche
Study Chair: Armando Gabrielli, MD Università Politecnica delle Marche
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Paolo Fraticelli/MD, Università Politecnica delle Marche Identifier: NCT00573326     History of Changes
Other Study ID Numbers: FARM 69J AJ9
EudraCT code:2007-005322-68
Study First Received: December 13, 2007
Last Updated: September 2, 2009

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Connective Tissue Diseases
Skin Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017